{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:11:45Z","timestamp":1775265105525,"version":"3.50.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Failure rates of second-line boosted protease inhibitor antiretroviral therapy regimens in children rise over time. Therapeutic drug monitoring can contribute to assessments of adherence. The authors assessed the performance characteristics of the US DHHS-recommended lopinavir (LPV) concentration of 1.0 mg\/L for predicting virologic failure (VF) and intermediate- to high-level LPV resistance in Asian children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>LPV concentration, HIV RNA level, and adherence data from study participants in Thailand, Vietnam, and Indonesia receiving second-line LPV-based ART and followed for \u226524 weeks were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 223 children at a median age of 10.4 (interquartile range, 7.9\u201313.4) years were enrolled, and 61% of them were male. Their mean CD4 was 842 \u00b1 438 cells per cubic millimeter, and the median LPV duration was 2.5 (interquartile range, 1.3\u20134.2) years. Five of 84 (6%) and 18 of 139 (13%) children had LPV trough and random concentrations &lt;1.0 mg\/L at study week 24. Using either of these trough or random LPV concentrations, a cutoff at 1.0 mg\/L gave an area under the receiver operating characteristics curve of 0.69 in predicting VF with sensitivity of 44% (95% CI 23\u201366) and specificity of 94% (95% CI 89\u201397). Seven of 21 with VF and resistance results available had \u22651 major protease inhibitor mutation. Multivariate logistic regression found LPV concentrations &lt;1.0 mg\/L (odds ratio, 6.47; 95% CI 2.15\u201319.50, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001) and CD4 \u226420% (odds ratio, 2.83; 95% CI 1.01\u20137.89, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.05) were independently associated with HIV RNA &gt;1000 copies per milliliter. No factors predicted major LPV resistance mutations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The authors support that the DHHS target LPV concentration of &lt;1.0 mg\/L is predictive of VF, but not of the presence of major LPV mutations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000329","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T12:03:10Z","timestamp":1475582590000},"page":"791-795","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Drug Monitoring of Lopinavir in HIV-Infected Children on Second-Line Antiretroviral Therapy in Asia"],"prefix":"10.1097","volume":"38","author":[{"given":"Linda","family":"Aurpibul","sequence":"first","affiliation":[{"name":"Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirinya","family":"Teerananchai","sequence":"additional","affiliation":[{"name":"The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, Bangkok, Thailand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasana","family":"Prasitsuebsai","sequence":"additional","affiliation":[{"name":"The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, Bangkok, Thailand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tavitiya","family":"Sudjaritruk","sequence":"additional","affiliation":[{"name":"Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand;"},{"name":"Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pope","family":"Kosalaraksa","sequence":"additional","affiliation":[{"name":"Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nia","family":"Kurniati","sequence":"additional","affiliation":[{"name":"Cipto Mangunkusumo General Hospital, Jakarta, Indonesia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khanh Huu","family":"Truong","sequence":"additional","affiliation":[{"name":"Children's Hospital 1, Ho Chi Minh City, Vietnam;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viet Chau","family":"Do","sequence":"additional","affiliation":[{"name":"Children's Hospital 2, Ho Chi Minh City, Vietnam;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lam Van","family":"Nguyen","sequence":"additional","affiliation":[{"name":"National Hospital of Pediatrics, Hanoi, Vietnam;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kulkanya","family":"Chokephaibulkit","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thida","family":"Singtoroj","sequence":"additional","affiliation":[{"name":"TREAT Asia\/amfAR\u2014The Foundation for AIDS Research, Bangkok, Thailand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Kerr","sequence":"additional","affiliation":[{"name":"The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, Bangkok, Thailand;"},{"name":"The Kirby Institute, UNSW Australia, Sydney, Australia; and"},{"name":"Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the TASER-Pediatrics Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1089\/apc.2009.0224","article-title":"Pediatric HIV clinical care resources and management practices in Asia: a regional survey of the TREAT Asia pediatric network","volume":"24","author":"Prasitsuebsai","year":"2010","journal-title":"AIDS Patient Care and STDs."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1742-6405-9-20","article-title":"High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting","volume":"9","author":"Puthanakit","year":"2012","journal-title":"AIDS Res Ther."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/135965350901400218","article-title":"Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir\/ritonavir, in pretreated children at 96 weeks","volume":"14","author":"Bunupuradah","year":"2009","journal-title":"Antivir Ther."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328351f5b2","article-title":"Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis","volume":"26","author":"Ajose","year":"2012","journal-title":"AIDS"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/cid\/civ271","article-title":"Treatment failure in HIV-infected children on second-line protease inhibitor-based antiretroviral therapy","volume":"61","author":"Suaysod","year":"2015","journal-title":"Clin Infect Dis."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/QAI.0b013e31820dc0cc","article-title":"Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting","volume":"56","author":"van Zyl","year":"2011","journal-title":"J Acquir Immune Defic Syndr."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/FTD.0b013e31820fa528","article-title":"The international interlaboratory quality control program for measurement of antiretroviral drugs in plasma: a global proficiency testing program","volume":"33","author":"Burger","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3851\/IMP2749","article-title":"Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen","volume":"19","author":"Moholisa","year":"2014","journal-title":"Antivir Ther."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/135965350400900508","article-title":"California Collaborative Treatment Group. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients","volume":"9","author":"Yasuda","year":"2004","journal-title":"Antivir Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201612000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:10:00Z","timestamp":1692051000000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201612000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000329","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}